DIRS.INFO The most relevant business & tech news

On a more positive note, Guggenheim upgraded GSK to buy thanks to strength across multiple product pipelines. Elsewhere, RBC upgraded Lyft to outperform, calling for a major rally ahead. Analyst Brad Erickson upgraded Lyft shares to outperform from sector perform, and raised his price target by $6 to $23, implying roughly 40.7% potential increase. — Pia Singh 6:10 a.m.: DoorDash upgraded by RBC on new partnerships potential, higher order growth RBC Capital Markets upgraded DoorDash to outperform from sector perform. Analyst Seamus Fernandez upgraded shares to buy from neutral and assigned a £20.31 price target, representing 21% upside to GSK's latest close.

Persons: Guggenheim, Wells Fargo, Timur Braziler, Braziler, — Pia Singh, Lyft, Brad Erickson, Erickson, Seamus Fernandez, Fernandez, Citi downgrades Ferrari, Ferrari, Harald Hendrikse, Fred Imbert Organizations: CNBC, Citi, Ferrari, GSK, RBC, Popular, RBC Capital Markets RBC Capital Markets, DASH, Capital Markets, Guggenheim Securities, drugmaker GSK, Guggenheim Locations: Wells Fargo, Puerto Rico, U.S, Wells, Shingrix, Arexvy, Milan

UBS hiked its price target on Nvidia , citing an attractive valuation and strong demand for its chips. The firm upgraded shares to overweight from neutral and upped its target price by $17 to $68, which implies 24.3% potential upside. He upgraded shares to buy from neutral and increased his price target from £17 to £21. — Pia Singh 5:47 a.m.: UBS hikes Nvidia price target UBS is getting even more bullish on Nvidia ahead of the chipmaker's fiscal fourth-quarter earnings report. Despite the price target increase, Nvidia shares were down 1% in the premarket.

Persons: Riley Securities downgrades, Jeff Lick, Children's, Lick, — Pia Singh, Piper Sandler, Trimble, Clarke Jeffries, Mark Palmer, Palmer, Andrew Baum, Baum, GSK's, Timothy Arcuri, Arcuri, NVDA, Fred Imbert Organizations: CNBC, UBS, Nvidia, Citi, GSK, Riley Securities, Children's, Investment, Block Locations: Lick, Monday's, C2H

☆ Standard Chartered Bank China starts digital yuan exchange services
▼ + stars: | 2023-11-27 | by ( ) www.reuters.com time to read: 1 min

Healthcare & Pharmaceuticals category · November 27, 2023 · 11:26 AM UTC · ago · agoGSK said on Monday that its blood cancer drug Blenrep had reached a key goal in a late-stage trial, as the British drugmaker looks to bolster its oncology business after a series of setbacks.

Persons: Blenrep Organizations: Pharmaceuticals, GSK Locations: British

☆ How GSK plans to replenish its depleted medicine cabinet
▼ + stars: | 2023-03-15 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

GSK has since suffered a series of clinical trial setbacks in its cancer drugs portfolio, most recently last year involving ovarian cancer drug Zejula and blood cancer drug Blenrep. BLOCKBUSTER POTENTIALAnalysts say that despite a string of strong quarterly earnings, lingering concerns over the company's drug pipeline reflect in GSK's share price. The investor said he does not see enough GSK drugs, either on the market or in development, with potential to be a so-called "blockbusters" with annual sales exceeding $1 billion. But Wood said the overhauled R&D department has put GSK in a strong position to meet growth targets. U.S. regulatory approval on GSK's vaccine, and a rival vaccine developed by Pfizer, is expected in May.

☆ GSK to stop selling blood cancer drug Blenrep in United States
▼ + stars: | 2022-11-22 | by ( Pushkala Aripaka | ) www.reuters.com time to read: +2 min

GSK said access to Blenrep in other countries where it is marketed is unaffected, including across the European Union. The company is still discussing the latest clinical data with EU health authorities, a GSK official said. The drug was given speedy approval by the FDA in 2020 and approved for patients with relapsed or refractory multiple myeloma who received at least four previous therapies. Last year the drug achieved 89 million pounds ($105 million) in global sales, about two thirds of which was from the United States. Blenrep belongs to a category of treatments called antibody drug conjugates, which are engineered antibodies that bind to tumour cells and then release cell-killing chemicals.

☆ FTSE 100 hits two-month high as oil stocks rebound
▼ + stars: | 2022-11-22 | by ( ) www.reuters.com time to read: +1 min

SummarySummary Companies FTSE 100 up 0.6%, FTSE 250 off 0.2%Nov 22 (Reuters) - The FTSE 100 jumped to a two-month high on Tuesday, as oil stocks bounced back following a bullish brokerage recommendation and news that OPEC+ members were not discussing an oil output increase. The commodities-heavy FTSE 100 (.FTSE) rose 0.6% to its strongest level since Sept. 13. Oil majors Shell and BP (BP.L) jumped 2.9% and 4.8% as crude prices , gained after Saudi Arabia's energy minister denied a report that said OPEC oil producers were discussing a potential output increase. Meanwhile, Citigroup raised BP's rating to "buy" from "neutral" and said it expects the rotation into energy stocks to continue. The more domestically focused FTSE 250 midcaps (.FTMC) slipped 0.2%, reflecting a cautious mood in the equities market on concerns about aggressive rate hikes and slowing economic growth.

The news marks a second setback for GSK's oncology portfolio this week, after the company on Monday revealed its blood cancer drug Blenrep failed to outperform an older therapy in a key study, calling into question Blenrep's existing U.S. approval. Zejula belongs to a family of drugs called PARP inhibitors - which include AstraZeneca (AZN.L) and Merck's (MRK.N) Lynparza and Clovis Oncology's (CLVS.O) Rubraca. In September, GSK withdrew the use of Zejula in certain ovarian cancer patients who had previously undergone three or more chemotherapy regimens. For GSK, Zejula's use in the first-line setting - as a therapy designed to keep cancer at bay in ovarian cancer patients who have partially or fully benefited from platinum-based chemotherapy, remains a priority. Zejula - which GSK acquired through its $5.1 billion acquisition of U.S. cancer specialist Tesaro in 2018 - generated a total of 120 million pounds ($141.4 million) last quarter.

☆ GSK's blood cancer drug fails main goal of trial, shares fall
▼ + stars: | 2022-11-07 | by ( Pushkala Aripaka | ) www.reuters.com time to read: +2 min

SummarySummary Companies Data calls into question existing drug approval -analystsGSK in talks with health authorities, other trials continuingShares fall 3%Nov 7 (Reuters) - GSK's (GSK.L) blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market, the company said on Monday. In April, the company agreed to buy U.S. drug developer Sierra Oncology, gaining access to its main experimental drug for a rare blood cancer and complementing GSK's Blenrep. In the trial, Blenrep was compared with a combination of pomalidomide and low doses of the steroid dexamethasone. Pomalidomide was developed by Celgene, now part of Bristol-Myers Squibb , and was approved in 2013 as a treatment for multiple myeloma. The drug belongs to a promising category of treatments called antibody drug conjugates, which are engineered antibodies that bind to tumour cells and then release cell-killing chemicals.

☆ Miners, energy stocks drag FTSE 100 as China upholds COVID policy
▼ + stars: | 2022-11-07 | by ( ) www.reuters.com time to read: +1 min

SummarySummary Companies FTSE 100 down 0.5%, FTSE 250 off 0.1%Nov 7 (Reuters) - UK's export-oriented FTSE 100 started the week on a lacklustre note, dragged down by energy and mining stocks, as China dampened hopes of a rebound in commodity demand after it reiterated its zero-COVID policy to curb outbreaks. The blue-chip FTSE 100 (.FTSE) fell 0.5% on Monday, while the mid-cap FTSE 250 (.FTMC) was down 0.1% by 0808 GMT. Energy stocks (.FTNMX601010) and miners (.FTNMX551030) were off 1.1% and 0.2%, respectively, tracking commodity prices that were hit as stringent COVID-19 curbs darkened demand outlook from China. METL/Mortgage lender Halifax said British house prices fell in October at the fastest monthly rate since February 2021. Reporting by Johann M Cherian in Bengaluru; Editing by Sherry Jacob-PhillipsOur Standards: The Thomson Reuters Trust Principles.

☆ Johnson & Johnson's blood cancer therapy gets U.S. FDA approval
▼ + stars: | 2022-10-25 | by ( Khushi Mandowara | ) www.reuters.com time to read: +2 min

Oct 25 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's (JNJ.N) therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer. Tecvayli is a bispecific antibody, which is engineered to redirect body's immune system to recognize and kill cancer cells. It is the first drug of its class to be approved for multiple myeloma. Though multiple myeloma is rare compared to breast or prostate cancer, it is a common type of blood cancer, which develops in the bone marrow and can spread throughout the body. According to the American Cancer Society's estimates, close to 35,000 new cases of multiple myeloma are likely to be diagnosed in the United States this year.

Search resuls for: "Blenrep"

10 mentions found